Compound B as an angiogenic agent in combination with human growth factors
View Patent ↗Compound B is shown to promote angiogenesis, specifically, budding of capillaries. The combination of Compound B and with human growth factor, such as bFGF, shows synergistic angiogenetic effects.
1. A method of promoting angiogenesis in a patient in need thereof, comprising administering to the patient Component B and a human growth factor, for a time sufficient and in amounts effective for the promotion of angiogenesis in the patient, wherein said Component B and said human growth factor are administered such that they will be simultaneously present in the blood of the patient in amounts effective for the promotion of angiogenesis in the patient.
2. The method of claim 1 , wherein the angiogenesis is in relation to the treatment of a wound, ulcer or other traumatic lesion to the tissues of the body of the patient.
3. The method of claim 1 , wherein the Component B and the human growth factor are administered in a single composition.
4. The method of claim 2 , wherein the Component B and the human growth factor are administered in a single composition.
5. The method of claim 1 , wherein the Component B and the human growth factor are administered in separate compositions.
6. The method of claim 2 , wherein the Component B and the human growth factor are administered in separate compositions.
7. The method of claim 1 , wherein the ratio of the amount of Component B to the amount of the human growth factor is selected to provide synergistic angiogenesis results.
8. A method of treating a wound, ulcer or other traumatic lesion in a patient in need thereof, comprising administering to the patient Component B and a human growth factor, for a time sufficient and in an amount effective for the treatment of the wound, ulcer or other traumatic lesion in the patient, wherein said Component B and said human growth factor are administered such that they will be simultaneously present in the blood of the patient in amounts effective for the treatment of the wound, ulcer or other traumatic lesion in the patient.
9. The method of claim 8 , wherein the Component B and the human growth factor are administered in separate administration doses.
10. The method of claim 8 , wherein the ratio of the amount of Component B to the amount of the human growth factor is selected to provide synergistic results.
11. A pharmaceutical composition for promoting angiogenesis, comprising Component B and a human growth factor, in combination with a pharmaceutically acceptable carrier, wherein the ratio of the amount of Component B to the amount of human growth factor is selected to provide synergistic angiogenesis results when administered to a patient in need thereof.
12. A pharmaceutical composition for treating a wound, ulcer or other traumatic lesion, comprising Component B and a human growth factor, in combination with a pharmaceutically acceptable carrier, wherein the ratio of the amount of Component B to the amount of human growth factor is selected to provide synergistic results when administered to a patient in need thereof.
13. A method for promoting angiogenesis in a patient in need thereof, comprising administering to the patient, by oral, intravenous, intramuscular or subcutaneous route, an effective amount of Component B, wherein said Component B is administered in a slow-release formulation.
14. The method of claim 13 , wherein the angiogenesis is in relation to the treatment of a wound, ulcer or other traumatic lesion to the tissues of the body of the patient.
15. A method for eliciting the budding of capillaries in a patient in need thereof, comprising administering to the patient an effective amount of Component, wherein said Component B is administered in a slow-release formulation.
16. The method of claim 15 , wherein the budding of capillaries is in relation to the treatment of a wound, ulcer or other traumatic lesion to the tissues of the body of the patient.